Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina

Uložené v:
Podrobná bibliografia
Názov: Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina
Autori: Gagliardino, Juan Jose, Elgart, Jorge Federico, Forti, Luján, Querzoli, Ivanna, Chantelot, Jean Marc
Zdroj: Diabetes Research and Clinical Practice. 153:86-92
Informácie o vydavateľovi: Elsevier BV, 2019.
Rok vydania: 2019
Predmety: Male, TREATMENT GOALS ATTAINMENT, Argentina, HBA1C AND INSULIN TREATMENT, Middle Aged, 3. Good health, 03 medical and health sciences, PRESCRIPTION STYLE, Treatment Outcome, 0302 clinical medicine, Diabetes Mellitus, Type 2, QUALITY OF CARE, Surveys and Questionnaires, Humans, Female, COMBINED TREATMENT GOALS
Popis: To assess prescription patterns for treatment of type 2 diabetes (T2D) and their outcomes in the IDMPS survey in Argentina.Data from 2551 people with T2D recruited from 210 physicians participating in IDMPS surveys in Argentina (2006 to 2012 waves) were recorded, including medical history, medications, glycemic control, blood pressure, and lipid status.Most people were treated with oral glucose-lowering drugs (OGLDs) (65%), followed by combinations of these drugs plus insulin (22%) and only insulin (13%). These percentages varied according to T2D duration, the frequency of OGLDs decreasing while contrastingly and only insulin increasing (under 5 years versus over 10 years of disease duration, respectively). Average systolic blood pressure (SBP), HbA1c and LDL-c were significantly higher in patients treated with insulin either alone or associated with OGLDs. The percentage of people at target values for these parameters was also lower in these two groups. The percentage of people that reached simultaneous goal treatment values for BP, HbA1c and LDL-c levels was markedly low.Prescription patterns for treatment of T2D follows a chronological trend and the percentage of people at goal values (HbA1c, BP and LDL-c values) was significantly lower in people receiving insulin. These data must be carefully considered by health and academic authorities in order to implement effective strategies to modify this situation.
Druh dokumentu: Article
Popis súboru: application/pdf
Jazyk: English
ISSN: 0168-8227
DOI: 10.1016/j.diabres.2019.05.008
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/31102686
https://www.ncbi.nlm.nih.gov/pubmed/31102686
https://www.sciencedirect.com/science/article/pii/S0168822718317686
https://ri.conicet.gov.ar/handle/11336/122469
https://pubmed.ncbi.nlm.nih.gov/31102686/
https://notablesdelaciencia.conicet.gov.ar/handle/11336/122469
http://hdl.handle.net/11336/122469
Rights: Elsevier TDM
CC BY NC SA
Prístupové číslo: edsair.doi.dedup.....6677e23f9a1c10015e9ff3f0d93a38c8
Databáza: OpenAIRE
Popis
Abstrakt:To assess prescription patterns for treatment of type 2 diabetes (T2D) and their outcomes in the IDMPS survey in Argentina.Data from 2551 people with T2D recruited from 210 physicians participating in IDMPS surveys in Argentina (2006 to 2012 waves) were recorded, including medical history, medications, glycemic control, blood pressure, and lipid status.Most people were treated with oral glucose-lowering drugs (OGLDs) (65%), followed by combinations of these drugs plus insulin (22%) and only insulin (13%). These percentages varied according to T2D duration, the frequency of OGLDs decreasing while contrastingly and only insulin increasing (under 5 years versus over 10 years of disease duration, respectively). Average systolic blood pressure (SBP), HbA1c and LDL-c were significantly higher in patients treated with insulin either alone or associated with OGLDs. The percentage of people at target values for these parameters was also lower in these two groups. The percentage of people that reached simultaneous goal treatment values for BP, HbA1c and LDL-c levels was markedly low.Prescription patterns for treatment of T2D follows a chronological trend and the percentage of people at goal values (HbA1c, BP and LDL-c values) was significantly lower in people receiving insulin. These data must be carefully considered by health and academic authorities in order to implement effective strategies to modify this situation.
ISSN:01688227
DOI:10.1016/j.diabres.2019.05.008